Bryant D. Lim - 14 May 2024 Form 4 Insider Report for Prelude Therapeutics Inc (PRLD)

Role
CLO, Interim CFO, Corp Sec.
Signature
/s/ Krishna Vaddi, Attorney-in-Fact
Issuer symbol
PRLD
Transactions as of
14 May 2024
Net transactions value
$0
Form type
4
Filing time
16 May 2024, 16:00:43 UTC
Previous filing
04 Mar 2024
Next filing
20 Dec 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRLD Employee Stock Option (Right to Buy) Award $0 +25,000 $0.000000 25,000 14 May 2024 Common Stock 25,000 $3.86 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 25% of the total shares on May 14, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.